Oric Pharmaceuticals presents promising enozertinib data and plans Phase 3 trial for 2027, impacting the oncology pharmaceutical sector.
| Name | Oric Pharmaceuticals, Inc. |
|---|---|
| CIK | 0001796280 |
| Tickers | ORIC |
| Exchanges | Nasdaq |
| Entity type | operating |
| Category | Non-accelerated filer |
| SIC | 2834 Pharmaceutical Preparations |
| EIN | 471787157 |
| LEI | — |
| Fiscal year end | 1231 |
| State of incorporation | DE DE |
| Phone | (650) 388-5600 |
| Website | — |
| Investor website | — |
| Owner org | 03 Life Sciences |
| Flags | — |
| Description | — |
| Insider transactions (issuer) | 1 |
| Insider transactions (owner) | 0 |
EDGAR has no company-logo API. Website field is shown when the filer provided one.
Oric Pharmaceuticals presents promising enozertinib data and plans Phase 3 trial for 2027, impacting the oncology pharmaceutical sector.
Oric Pharmaceuticals CFO Dominic Piscitelli reports significant stock transactions, reflecting changes in executive compensation strategies in the pharmaceutical industry.
Oric Pharmaceuticals' director Richard A. Heyman disclosed stock transactions, including acquisitions and disposals, highlighting ongoing activity in the pharmaceutical sector.
428 filing rows loaded from submissions recent.
| Filed | Form | Document | Items | Accession | File no. | Film | Act | Size | XBRL | iXBRL |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000905148-26-004951 | 005-91490 | 261562269 | 34 | 39402 | |||
| 2026-11-16 | 10-Q | 10-Q | 0001193125-26-463577 | 001-39269 | 261561402 | 34 | 7583893 | 1 | 1 | |
| 2026-11-16 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-463506 | 001-39269 | 261560849 | 34 | 455102 | 1 | 1 |
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000935836-26-000590 | 005-91490 | 261559321 | 34 | 15904 | |||
| 2026-11-16 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000080255-26-000706 | 005-91490 | 261556441 | 34 | 7864 | |||
| 2026-10-23 | 8-K | 8-K | 7.01,8.01,9.01 | 0001193125-26-429465 | 001-39269 | 261479932 | 34 | 20334273 | 1 | 1 |
| 2026-10-21 | 4 | xslF345X06/form4-10212026_091012.xml | 0001695028-26-000012 | 9043 | ||||||
| 2026-10-02 | 4 | xslF345X06/form4-10022026_091044.xml | 0001584759-26-000017 | 10842 | ||||||
| 2026-10-01 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-001030 | 001-39269 | 261431668 | 33 | 8373 | |||
| 2026-10-01 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-001029 | 001-39269 | 261431654 | 33 | 7729 | |||
| 2026-09-29 | 4 | xslF345X06/form4-09292026_110919.xml | 0001695028-26-000010 | 9044 | ||||||
| 2026-09-25 | 4 | xslF345X06/form4-09252026_110926.xml | 0001695028-26-000008 | 10107 | ||||||
| 2026-08-28 | 4 | xslF345X06/form4-08282026_080834.xml | 0001695028-26-000006 | 12569 | ||||||
| 2026-08-26 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000883 | 001-39269 | 261322936 | 33 | 7381 | |||
| 2026-08-03 | 10-Q | 10-Q | 0001193125-26-330631 | 001-39269 | 261233220 | 34 | 7047165 | 1 | 1 | |
| 2026-08-03 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-330568 | 001-39269 | 261232934 | 34 | 423978 | 1 | 1 |
| 2026-07-30 | S-8 | S-8 | 0001193125-26-326363 | 333-297837 | 261224544 | 33 | 212111 | 1 | 1 | |
| 2026-07-30 | 8-K | 8-K | 5.02,9.01 | 0001193125-26-326309 | 001-39269 | 261224141 | 34 | 257207 | 1 | 1 |
| 2026-07-28 | 4 | xslF345X06/form4-07282026_080709.xml | 0001584759-26-000015 | 10385 | ||||||
| 2026-07-08 | 4 | xslF345X06/form4-07082026_080727.xml | 0001584759-26-000012 | 5841 | ||||||
| 2026-07-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000699 | 001-39269 | 261156274 | 33 | 5570 | |||
| 2026-07-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000698 | 001-39269 | 261156268 | 33 | 4928 | |||
| 2026-06-22 | 8-K | 8-K | 5.02,5.07,9.01 | 0001193125-26-277511 | 001-39269 | 261107015 | 34 | 447786 | 1 | 1 |
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000905148-26-002430 | 005-91490 | 26990047 | 34 | 39155 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0001738048-26-000058 | 005-91490 | 26988667 | 34 | 17954 | |||
| 2026-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X02/primary_doc.xml | 0000919574-26-003469 | 005-91490 | 26987866 | 34 | 11215 | |||
| 2026-05-15 | SCHEDULE 13G | xslSCHEDULE_13G_X02/primary_doc.xml | 0000080255-26-000420 | 005-91490 | 26983452 | 34 | 7653 | |||
| 2026-05-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000078003-26-000067 | 005-91490 | 26969714 | 34 | 8948 | |||
| 2026-05-04 | 10-Q | 10-Q | 0001193125-26-204047 | 001-39269 | 26937947 | 34 | 6473010 | 1 | 1 | |
| 2026-05-04 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-203993 | 001-39269 | 26937662 | 34 | 381155 | 1 | 1 |
| 2026-04-28 | ARS | ARS | 0001193125-26-186947 | 001-39269 | 26907676 | 34 | 2466619 | |||
| 2026-04-28 | DEFA14A | DEFA14A | 0001193125-26-186921 | 001-39269 | 26907550 | 34 | 536224 | |||
| 2026-04-28 | DEF 14A | DEF 14A | 0001193125-26-186911 | 001-39269 | 26907507 | 34 | 3169296 | 1 | 1 | |
| 2026-03-31 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-134618 | 001-39269 | 26822107 | 34 | 22563066 | 1 | 1 |
| 2026-02-26 | 4 | xslF345X05/form4-02262026_090218.xml | 0001695028-26-000004 | 8908 | ||||||
| 2026-02-24 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000149 | 001-39269 | 26671604 | 33 | 4395 | |||
| 2026-02-23 | 8-K | 8-K | 8.01,9.01 | 0001193125-26-064291 | 001-39269 | 26666284 | 34 | 188353 | 1 | 1 |
| 2026-02-23 | 424B5 | 424B5 | 0001193125-26-064275 | 333-277829 | 26666233 | 33 | 475009 | 1 | 1 | |
| 2026-02-23 | S-8 | S-8 | 0001193125-26-064243 | 333-293661 | 26666133 | 33 | 212134 | 1 | 1 | |
| 2026-02-23 | 10-K | 10-K | 0001193125-26-064005 | 001-39269 | 26665356 | 34 | 20705343 | 1 | 1 | |
| 2026-02-23 | 8-K | 8-K | 2.02,9.01 | 0001193125-26-063974 | 001-39269 | 26665242 | 34 | 410012 | 1 | 1 |
| 2026-02-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001738048-26-000026 | 005-91490 | 26644149 | 34 | 17823 | |||
| 2026-01-21 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0002012383-26-000702 | 005-91490 | 26545869 | 34 | 10902 | |||
| 2026-01-20 | 4 | xslF345X05/form4-01212026_120124.xml | 0001584759-26-000006 | 7021 | ||||||
| 2026-01-16 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000038 | 001-39269 | 26540213 | 33 | 4562 | |||
| 2026-01-16 | 144 | xsl144X01/primary_doc.xml | 0001968582-26-000036 | 001-39269 | 26540071 | 33 | 4449 | |||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090103.xml | 0001647664-26-000002 | 5422 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090157.xml | 0001536368-26-000002 | 5419 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090105.xml | 0001533451-26-000002 | 5426 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090104.xml | 0001584759-26-000003 | 5384 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090138.xml | 0001574591-26-000002 | 5406 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090131.xml | 0001695028-26-000002 | 7963 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090111.xml | 0001586894-26-000002 | 7964 | ||||||
| 2026-01-06 | 4 | xslF345X05/form4-01062026_090105.xml | 0001608936-26-000002 | 7935 | ||||||
| 2025-12-17 | 4 | xslF345X05/form4-12182025_121256.xml | 0001586894-25-000005 | 14078 | ||||||
| 2025-12-17 | 4 | xslF345X05/form4-12182025_121249.xml | 0001695028-25-000008 | 14061 | ||||||
| 2025-12-17 | 4 | xslF345X05/form4-12182025_121249.xml | 0001608936-25-000014 | 13851 | ||||||
| 2025-12-16 | 144 | xsl144X01/primary_doc.xml | 0001695028-25-000007 | 001-39269 | 251577096 | 33 | 5060 | |||
| 2025-12-16 | 144 | xsl144X01/primary_doc.xml | 0001586894-25-000004 | 001-39269 | 251577088 | 33 | 4413 | |||
| 2025-12-16 | 144 | xsl144X01/primary_doc.xml | 0001608936-25-000013 | 001-39269 | 251577082 | 33 | 7024 | |||
| 2025-12-09 | 4 | xslF345X05/form4-12092025_101258.xml | 0001536368-25-000006 | 7033 | ||||||
| 2025-12-08 | 8-K | 8-K | 8.01,9.01 | 0001193125-25-310472 | 001-39269 | 251554518 | 34 | 21886546 | 1 | 1 |
| 2025-12-05 | 4 | xslF345X05/form4-12052025_101227.xml | 0001536368-25-000004 | 7154 | ||||||
| 2025-11-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001193125-25-284976 | 005-91490 | 251492536 | 34 | 15000 | |||
| 2025-11-13 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-004920 | 005-91490 | 251480224 | 34 | 10699 | |||
| 2025-11-13 | 8-K | 8-K | 7.01,9.01 | 0001193125-25-280247 | 001-39269 | 251478931 | 34 | 1670980 | 1 | 1 |
| 2025-11-13 | 10-Q | 10-Q | 0001193125-25-280234 | 001-39269 | 251478851 | 34 | 7055211 | 1 | 1 | |
| 2025-11-13 | 8-K | 8-K | 2.02,9.01 | 0001193125-25-280196 | 001-39269 | 251478681 | 34 | 614803 | 1 | 1 |
| 2025-10-08 | 4 | xslF345X05/form4-10082025_091013.xml | 0001695028-25-000004 | 8908 | ||||||
| 2025-10-08 | 4 | xslF345X05/form4-10082025_091029.xml | 0001608936-25-000010 | 5690 | ||||||
| 2025-10-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-25-000980 | 001-39269 | 251377097 | 33 | 4545 | |||
| 2025-10-03 | 4 | xslF345X05/form4-10032025_111055.xml | 0001584759-25-000004 | 13443 | ||||||
| 2025-10-02 | 4 | xslF345X05/form4-10022025_111028.xml | 0001608936-25-000008 | 7684 | ||||||
| 2025-09-24 | 4 | xslF345X05/form4-09242025_080916.xml | 0001608936-25-000006 | 5874 | ||||||
| 2025-09-22 | 144 | xsl144X01/primary_doc.xml | 0001968582-25-000950 | 001-39269 | 251330479 | 33 | 4557 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000905148-25-002996 | 005-91490 | 251221305 | 34 | 42436 | |||
| 2025-08-14 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-021933 | 005-91490 | 251220530 | 34 | 14877 | |||
| 2025-08-14 | SCHEDULE 13D/A | xslSCHEDULE_13D_X01/primary_doc.xml | 0000950170-25-108850 | 005-91490 | 251218709 | 34 | 393052 | |||
| 2025-08-12 | 10-Q | 10-Q | 0000950170-25-107359 | 001-39269 | 251207027 | 34 | 6860047 | 1 | 1 | |
| 2025-08-12 | 8-K | 8-K | 2.02,2.05,9.01 | 0000950170-25-107313 | 001-39269 | 251206780 | 34 | 624424 | 1 | 1 |
| 2025-08-05 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000935836-25-000480 | 005-91490 | 251186611 | 34 | 15740 | |||
| 2025-07-17 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0002052113-25-003103 | 005-91490 | 251132276 | 34 | 10887 | |||
| 2025-07-02 | 4 | xslF345X05/form4-07022025_080708.xml | 0001415889-25-019000 | 5314 | ||||||
| 2025-06-24 | 4 | xslF345X05/form4-06242025_100608.xml | 0001415889-25-018128 | 8330 | ||||||
| 2025-06-24 | 424B3 | 424B3 | 0001193125-25-145721 | 333-287949 | 251068989 | 33 | 200408 | |||
| 2025-06-23 | 4 | xslF345X05/form4-06242025_120613.xml | 0001415889-25-018014 | 6554 | ||||||
| 2025-06-20 | EFFECT | xslEFFECTX01/primary_doc.xml | ,, | 9999999995-25-001981 | 333-287949 | 251062836 | 33 | 1780 | ||
| 2025-06-17 | CORRESP | filename1.htm | 0001193125-25-142046 | 8255 | ||||||
| 2025-06-16 | UPLOAD | filename1.pdf | 0000000000-25-006298 | 333-287949 | 40152 | |||||
| 2025-06-13 | 4 | xslF345X05/form4-06132025_110620.xml | 0001415889-25-017325 | 4871 | ||||||
| 2025-06-13 | 8-K | 8-K | 5.07 | 0001193125-25-140725 | 001-39269 | 251046463 | 34 | 146724 | 1 | 1 |
| 2025-06-11 | 4 | xslF345X05/form4-06112025_100647.xml | 0001415889-25-016739 | 8086 | ||||||
| 2025-06-11 | S-3 | S-3 | 0001193125-25-139139 | 333-287949 | 251039957 | 33 | 303389 | |||
| 2025-06-09 | 4 | xslF345X05/form4-06102025_120617.xml | 0001415889-25-016386 | 6819 | ||||||
| 2025-06-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-25-000467 | 001-39269 | 251030892 | 33 | 4524 | |||
| 2025-06-06 | D | xslFormDX01/primary_doc.xml | 06b | 0001796280-25-000001 | 021-548268 | 251029664 | 33 | 12206 | ||
| 2025-06-05 | SCHEDULE 13D | xslSCHEDULE_13D_X01/primary_doc.xml | 0000950170-25-082520 | 005-91490 | 251028164 | 34 | 462348 | |||
| 2025-06-04 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0000902664-25-002631 | 005-91490 | 251023600 | 34 | 17501 | |||
| 2025-05-30 | SCHEDULE 13G | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-015010 | 005-91490 | 251011601 | 34 | 34964 | |||
| 2025-05-28 | 8-K | 8-K | 1.01,3.02,7.01,8.01,9.01 | 0001193125-25-129531 | 001-39269 | 25996005 | 34 | 555373 | 1 | 1 |
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-013266 | 005-91490 | 25956183 | 34 | 24672 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000905148-25-001761 | 005-91490 | 25954331 | 34 | 38133 | |||
| 2025-05-15 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0001415889-25-012988 | 005-91490 | 25949393 | 34 | 57736 | |||
| 2025-05-05 | 10-Q | 10-Q | 0000950170-25-063564 | 001-39269 | 25913282 | 34 | 6148724 | 1 | 1 | |
| 2025-05-05 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-063540 | 001-39269 | 25913017 | 34 | 567752 | 1 | 1 |
| 2025-04-23 | ARS | ARS | 0001193125-25-091384 | 001-39269 | 25861700 | 34 | 52396431 | |||
| 2025-04-23 | DEFA14A | DEFA14A | 0001193125-25-091370 | 001-39269 | 25861545 | 34 | 188130 | |||
| 2025-04-23 | DEF 14A | DEF 14A | 0001193125-25-091359 | 001-39269 | 25861471 | 34 | 1713544 | 1 | 1 | |
| 2025-03-20 | S-8 | S-8 | 0001193125-25-059251 | 333-285959 | 25756821 | 33 | 100541 | |||
| 2025-03-14 | 8-K | 8-K | 5.02,9.01 | 0001193125-25-054784 | 001-39269 | 25739864 | 34 | 431529 | 1 | 1 |
| 2025-03-04 | 4 | xslF345X05/form4-03042025_100357.xml | 0001415889-25-006616 | 10755 | ||||||
| 2025-02-25 | 8-K | 8-K | 8.01,9.01 | 0001193125-25-035203 | 001-39269 | 25663971 | 34 | 176935 | 1 | 1 |
| 2025-02-18 | 10-K | 10-K | 0000950170-25-022273 | 001-39269 | 25635180 | 34 | 19756808 | 1 | 1 | |
| 2025-02-18 | 8-K | 8-K | 2.02,9.01 | 0000950170-25-022219 | 001-39269 | 25634961 | 34 | 605302 | 1 | 1 |
| 2025-02-12 | SCHEDULE 13G/A | xslSCHEDULE_13G_X01/primary_doc.xml | 0000315066-25-000894 | 005-91490 | 25612576 | 34 | 11491 | |||
| 2025-01-13 | 8-K | 8-K | 7.01,9.01 | 0001193125-25-005028 | 001-39269 | 25524965 | 34 | 17724016 | 1 | 1 |
| 2025-01-06 | 4 | xslF345X05/form4-01062025_090153.xml | 0001415889-25-000795 | 5429 | ||||||
| 2025-01-06 | 4 | xslF345X05/form4-01062025_090135.xml | 0001415889-25-000792 | 5428 | ||||||
| 2025-01-06 | 4 | xslF345X05/form4-01062025_090139.xml | 0001415889-25-000788 | 5433 | ||||||
| 2025-01-06 | 4 | xslF345X05/form4-01062025_090141.xml | 0001415889-25-000785 | 5398 | ||||||
| 2025-01-06 | 4 | xslF345X05/form4-01062025_090133.xml | 0001415889-25-000782 | 5413 | ||||||
| 2025-01-03 | 4 | xslF345X05/form4-01032025_100144.xml | 0001415889-25-000602 | 7971 | ||||||
| 2025-01-03 | 4 | xslF345X05/form4-01032025_100150.xml | 0001415889-25-000601 | 7970 | ||||||
| 2025-01-03 | 4 | xslF345X05/form4-01032025_100156.xml | 0001415889-25-000600 | 7942 | ||||||
| 2024-12-17 | 4 | xslF345X05/form4-12172024_101232.xml | 0001415889-24-029634 | 14077 | ||||||
| 2024-12-17 | 4 | xslF345X05/form4-12172024_101230.xml | 0001415889-24-029633 | 14076 | ||||||
| 2024-12-17 | 4 | xslF345X05/form4-12172024_101258.xml | 0001415889-24-029631 | 14053 | ||||||
| 2024-12-16 | 144 | xsl144X01/primary_doc.xml | 0001796280-24-000007 | 001-39269 | 241553474 | 33 | 4419 | |||
| 2024-12-16 | 144 | xsl144X01/primary_doc.xml | 0001796280-24-000006 | 001-39269 | 241553473 | 33 | 4456 | |||
| 2024-12-16 | 144 | xsl144X01/primary_doc.xml | 0001796280-24-000005 | 001-39269 | 241553464 | 33 | 4416 | |||
| 2024-11-14 | SC 13G/A | oric13ga5.htm | 0000935836-24-000716 | 005-91490 | 241464819 | 34 | 48236 | |||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001104659-24-119315 | 005-91490 | 241464757 | 34 | 117357 | |||
| 2024-11-14 | SC 13G/A | SC 13G/A | 0001193125-24-258788 | 005-91490 | 241464275 | 34 | 75802 | |||
| 2024-11-13 | SC 13G/A | ORIC PHARMACEUTICALS, INC. | 0000902664-24-006454 | 005-91490 | 241451592 | 34 | 62130 | |||
| 2024-11-12 | 10-Q | 10-Q | 0000950170-24-125471 | 001-39269 | 241448565 | 34 | 6466976 | 1 | 1 | |
| 2024-11-12 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-125386 | 001-39269 | 241448162 | 34 | 416515 | 1 | 1 |
| 2024-11-12 | SC 13G/A | filing.txt | 0000315066-24-002779 | 005-91490 | 241444875 | 34 | 8119 | |||
| 2024-11-08 | SC 13G | us68622p1093_110824.txt | 0002012383-24-003654 | 005-91490 | 241439778 | 34 | 13886 | |||
| 2024-10-22 | SC 13G | us68622p1093_102224.txt | 0002012383-24-001558 | 005-91490 | 241387308 | 34 | 13874 | |||
| 2024-08-12 | 10-Q | 10-Q | 0000950170-24-095467 | 001-39269 | 241197075 | 34 | 6347948 | 1 | 1 | |
| 2024-08-12 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-095419 | 001-39269 | 241196849 | 34 | 428786 | 1 | 1 |
| 2024-06-14 | 4 | xslF345X05/form4-06142024_080646.xml | 0001415889-24-016916 | 5564 | ||||||
| 2024-06-14 | 4 | xslF345X05/form4-06142024_080645.xml | 0001415889-24-016913 | 5563 | ||||||
| 2024-06-14 | 4 | xslF345X05/form4-06142024_080617.xml | 0001415889-24-016909 | 5568 | ||||||
| 2024-06-14 | 4 | xslF345X05/form4-06142024_080637.xml | 0001415889-24-016906 | 5548 | ||||||
| 2024-06-14 | 4 | xslF345X05/form4-06142024_080630.xml | 0001415889-24-016903 | 5533 | ||||||
| 2024-06-14 | 8-K | 8-K | 5.07 | 0001193125-24-161593 | 001-39269 | 241044730 | 34 | 155128 | 1 | 1 |
| 2024-06-04 | 4 | xslF345X05/form4-06042024_100642.xml | 0001415889-24-015475 | 7168 | ||||||
| 2024-05-06 | 10-Q | 10-Q | 0000950170-24-053582 | 001-39269 | 24917825 | 34 | 5827232 | 1 | 1 | |
| 2024-05-06 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-053551 | 001-39269 | 24917574 | 34 | 381724 | 1 | 1 |
| 2024-04-24 | ARS | ARS | 0001193125-24-110119 | 001-39269 | 24870773 | 34 | 3088330 | |||
| 2024-04-24 | DEFA14A | DEFA14A | 0001193125-24-110091 | 001-39269 | 24870673 | 34 | 425541 | |||
| 2024-04-24 | DEF 14A | DEF 14A | 0001193125-24-110069 | 001-39269 | 24870584 | 34 | 509195 | |||
| 2024-03-29 | S-8 | S-8 | 0001193125-24-082131 | 333-278394 | 24804586 | 33 | 98297 | |||
| 2024-03-29 | 8-K | 8-K | 5.02,9.01 | 0001193125-24-082077 | 001-39269 | 24804268 | 34 | 267529 | 1 | 1 |
| 2024-03-11 | S-3ASR | S-3ASR | 0001193125-24-064987 | 333-277829 | 24739252 | 33 | 868351 | |||
| 2024-03-11 | 10-K | 10-K | 0000950170-24-029298 | 001-39269 | 24738307 | 34 | 13755857 | 1 | 1 | |
| 2024-03-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-24-029239 | 001-39269 | 24738071 | 34 | 414629 | 1 | 1 |
| 2024-03-11 | SC 13G/A | filing.txt | 0000315066-24-001676 | 005-91490 | 24736616 | 34 | 8255 | |||
| 2024-03-08 | 4 | xslF345X05/form4-03082024_090337.xml | 0001415889-24-007345 | 5289 | ||||||
| 2024-03-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-24-000194 | 001-39269 | 24726282 | 33 | 5757 | |||
| 2024-02-14 | SC 13G/A | oric13ga4.htm | 0000935836-24-000217 | 005-91490 | 24641193 | 34 | 48598 | |||
| 2024-02-13 | SC 13G/A | oric13ga2024.htm | 0000935836-24-000150 | 005-91490 | 24630849 | 34 | 42397 | |||
| 2024-02-13 | SC 13G/A | SC 13G/A | 0001193125-24-033022 | 005-91490 | 24622927 | 34 | 109041 | |||
| 2024-02-09 | SC 13G/A | filing.txt | 0000315066-24-001351 | 005-91490 | 24611929 | 34 | 8322 | |||
| 2024-02-08 | 4 | xslF345X05/form4-02092024_010219.xml | 0001415889-24-003114 | 7239 | ||||||
| 2024-02-07 | SC 13G/A | us68622p1093_020724.txt | 0001086364-24-006812 | 005-91490 | 24605691 | 34 | 12580 | |||
| 2024-02-06 | SC 13G/A | ORIC_SC13GA.htm | 0001273087-24-000038 | 005-91490 | 24600395 | 34 | 81630 | |||
| 2024-02-06 | 144 | xsl144X01/primary_doc.xml | 0001968582-24-000089 | 001-39269 | 24600205 | 33 | 4499 | |||
| 2024-02-02 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2024-02-02 16:00:00 | 9999999995-24-000311 | 333-276719 | 24593783 | 33 | 1786 | ||
| 2024-02-01 | SC 13G | SC 13G | 0001104659-24-009469 | 005-91490 | 24587128 | 34 | 184186 | |||
| 2024-01-31 | CORRESP | filename1.htm | 0001193125-24-021092 | 7472 | ||||||
| 2024-01-31 | UPLOAD | filename1.pdf | 0000000000-24-001224 | 333-276719 | 40422 | |||||
| 2024-01-30 | SC 13G | SC 13G | 0001140361-24-004573 | 005-91490 | 24578613 | 34 | 357216 | |||
| 2024-01-30 | D | xslFormDX01/primary_doc.xml | 06b | 0001796280-24-000001 | 021-503858 | 24576739 | 33 | 12104 | ||
| 2024-01-29 | SC 13G | us68622p1093_012924.txt | 0001086364-24-005597 | 005-91490 | 24574924 | 34 | 13449 | |||
| 2024-01-26 | S-3 | S-3 | 0001193125-24-016819 | 333-276719 | 24568722 | 33 | 287636 | |||
| 2024-01-25 | SC 13G | SC 13G | 0001193125-24-015197 | 005-91490 | 24560838 | 34 | 330590 | |||
| 2024-01-22 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-24-011747 | 001-39269 | 24547222 | 34 | 379620 | 1 | 1 |
| 2024-01-09 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-24-004909 | 001-39269 | 24521898 | 34 | 22069194 | 1 | 1 |
| 2024-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-24-000368 | 8074 | ||||||
| 2024-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-24-000364 | 8073 | ||||||
| 2024-01-03 | 4 | FORM 4 SUBMISSION | 0001209191-24-000361 | 8043 | ||||||
| 2023-12-28 | EFFECT | xslEFFECTX01/primary_doc.xml | S-3,,2023-12-28 16:00:00 | 9999999995-23-003785 | 333-276077 | 231524194 | 33 | 1787 | ||
| 2023-12-26 | CORRESP | filename1.htm | 0001193125-23-303005 | 9526 | ||||||
| 2023-12-22 | UPLOAD | filename1.pdf | 0000000000-23-014043 | 40323 | ||||||
| 2023-12-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-059266 | 12075 | ||||||
| 2023-12-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-059264 | 12074 | ||||||
| 2023-12-19 | 4 | FORM 4 SUBMISSION | 0001209191-23-059263 | 12036 | ||||||
| 2023-12-15 | S-3 | S-3 | 0001193125-23-296691 | 333-276077 | 231490849 | 33 | 296696 | |||
| 2023-12-11 | 8-K | 8-K | 8.01,9.01 | 0001193125-23-292551 | 001-39269 | 231478172 | 34 | 174437 | 1 | 1 |
| 2023-11-06 | 10-Q | 10-Q | 0000950170-23-059415 | 001-39269 | 231380240 | 34 | 7608717 | 1 | 1 | |
| 2023-11-06 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-059392 | 001-39269 | 231380062 | 34 | 477909 | 1 | 1 |
| 2023-10-23 | 8-K | 8-K | 8.01,9.01 | 0001193125-23-260795 | 001-39269 | 231340078 | 34 | 186089 | 1 | 1 |
| 2023-08-10 | 10-Q | 10-Q | 0000950170-23-041362 | 001-39269 | 231159814 | 34 | 8077427 | 1 | 1 | |
| 2023-08-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-041326 | 001-39269 | 231159472 | 34 | 457786 | 1 | 1 |
| 2023-07-11 | 4 | FORM 4 SUBMISSION | 0001209191-23-042054 | 7256 | ||||||
| 2023-07-07 | 4 | FORM 4 SUBMISSION | 0001209191-23-041805 | 5258 | ||||||
| 2023-07-07 | SC 13G | SC 13G | 0001104659-23-079126 | 005-91490 | 231076942 | 34 | 109763 | |||
| 2023-07-05 | 144 | xsl144X01/primary_doc.xml | 0001968582-23-000305 | 001-39269 | 231068864 | 33 | 5047 | |||
| 2023-07-05 | D | xslFormDX01/primary_doc.xml | 06b | 0001796280-23-000001 | 021-485949 | 231068327 | 33 | 12118 | ||
| 2023-06-28 | 4 | FORM 4 SUBMISSION | 0001209191-23-040090 | 5439 | ||||||
| 2023-06-27 | 8-K | 8-K | 1.01,3.02,7.01,9.01 | 0001193125-23-175501 | 001-39269 | 231043918 | 34 | 492216 | 1 | 1 |
| 2023-06-26 | 144 | xsl144X01/primary_doc.xml | 0001968582-23-000278 | 001-39269 | 231043586 | 33 | 4419 | |||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037398 | 5490 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037396 | 5489 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037395 | 5494 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037394 | 5459 | ||||||
| 2023-06-15 | 4 | FORM 4 SUBMISSION | 0001209191-23-037393 | 5474 | ||||||
| 2023-06-15 | 8-K | 8-K | 5.07 | 0001193125-23-167893 | 001-39269 | 231017383 | 34 | 154489 | 1 | 1 |
| 2023-06-12 | SC 13G | SC 13G | 0001193125-23-164656 | 005-91490 | 231006865 | 34 | 125365 | |||
| 2023-05-08 | 10-Q | 10-Q | 0000950170-23-018839 | 001-39269 | 23898067 | 34 | 7445007 | 1 | 1 | |
| 2023-05-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-018807 | 001-39269 | 23897835 | 34 | 400203 | 1 | 1 |
| 2023-04-26 | ARS | ARS | 0001193125-23-118525 | 001-39269 | 23849836 | 34 | 1802282 | |||
| 2023-04-26 | DEFA14A | DEFA14A | 0001193125-23-118512 | 001-39269 | 23849784 | 34 | 288120 | |||
| 2023-04-26 | DEF 14A | DEF 14A | 0001193125-23-118496 | 001-39269 | 23849708 | 34 | 678981 | |||
| 2023-03-24 | 8-K | 8-K | 5.03,9.01 | 0001193125-23-079104 | 001-39269 | 23759901 | 34 | 393689 | 1 | 1 |
| 2023-03-16 | S-8 | S-8 | 0001193125-23-072705 | 333-270619 | 23739590 | 33 | 94386 | |||
| 2023-03-16 | 10-K | 10-K | 0000950170-23-008483 | 001-39269 | 23739126 | 34 | 13865481 | 1 | 1 | |
| 2023-03-16 | 8-K | 8-K | 2.02,9.01 | 0000950170-23-008457 | 001-39269 | 23738881 | 34 | 479703 | 1 | 1 |
| 2023-02-17 | 4/A | FORM 4/A SUBMISSION | 0001209191-23-010616 | 5171 | ||||||
| 2023-02-17 | 4/A | FORM 4/A SUBMISSION | 0001209191-23-010611 | 5171 | ||||||
| 2023-02-17 | 4/A | FORM 4/A SUBMISSION | 0001209191-23-010607 | 5085 | ||||||
| 2023-02-13 | SC 13G/A | oric13ga.htm | 0000935836-23-000129 | 005-91490 | 23615403 | 34 | 42195 | |||
| 2023-02-10 | SC 13G/A | oric13ga2022.htm | 0000935836-23-000103 | 005-91490 | 23610335 | 34 | 47368 | |||
| 2023-02-09 | SC 13G/A | filing.txt | 0000315066-23-001947 | 005-91490 | 23604825 | 34 | 8155 | |||
| 2023-02-06 | SC 13G/A | oricpharma13ga1_123122.htm | 0001040188-23-000047 | 005-91490 | 23588897 | 34 | 43857 | |||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006198 | 7961 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006195 | 7960 | ||||||
| 2023-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-23-006191 | 7930 | ||||||
| 2023-01-20 | SC 13G | ORIC_SC13G.htm | 0001273087-23-000043 | 005-91490 | 23541067 | 34 | 81560 | |||
| 2023-01-09 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-23-004194 | 001-39269 | 23516712 | 34 | 182943 | 1 | 1 |
| 2022-12-29 | SC 13G | SC 13G ORIC PHARMACEUTICALS | 0000078003-22-000112 | 005-91490 | 221499247 | 34 | 34873 | |||
| 2022-12-29 | 3 | PRIMARY DOCUMENT | 0000078003-22-000110 | 3770 | ||||||
| 2022-12-27 | SC 13D/A | AMENDMENT NO. 4 | 0000947871-22-001255 | 005-91490 | 221490746 | 34 | 113007 | |||
| 2022-12-21 | 8-K | 8-K | 8.01,9.01 | 0001193125-22-310169 | 001-39269 | 221479190 | 34 | 346666 | 1 | 1 |
| 2022-12-21 | 424B5 | 424B5 | 0001193125-22-310167 | 333-255833 | 221479181 | 33 | 548963 | |||
| 2022-12-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-061756 | 9205 | ||||||
| 2022-12-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-061755 | 9207 | ||||||
| 2022-12-16 | 4 | FORM 4 SUBMISSION | 0001209191-22-061754 | 9181 | ||||||
| 2022-11-07 | 10-Q | 10-Q | 0000950170-22-022631 | 001-39269 | 221365760 | 34 | 8285534 | 1 | 1 | |
| 2022-11-07 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-022600 | 001-39269 | 221365513 | 34 | 477406 | 1 | 1 |
| 2022-08-11 | 10-Q | 10-Q | 0000950170-22-016894 | 001-39269 | 221156188 | 34 | 7647556 | 1 | 1 | |
| 2022-08-11 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-016870 | 001-39269 | 221155831 | 34 | 451743 | 1 | 1 |
| 2022-07-21 | 4 | FORM 4 SUBMISSION | 0001209191-22-042843 | 17537 | ||||||
| 2022-07-21 | 4 | FORM 4 SUBMISSION | 0001209191-22-042842 | 22105 | ||||||
| 2022-07-21 | 4 | FORM 4 SUBMISSION | 0001209191-22-042841 | 17511 | ||||||
| 2022-07-21 | SC TO-I/A | SC TO-I/A | 0001193125-22-199146 | 005-91490 | 221097095 | 34 | 18476 | |||
| 2022-07-08 | SC 13G | us68622p1093_070822.txt | 0000834237-22-010293 | 005-91490 | 221075055 | 34 | 12215 | |||
| 2022-06-21 | SC TO-I | SC TO-I | 0001193125-22-177627 | 005-91490 | 221028189 | 34 | 10773442 | |||
| 2022-06-21 | 8-K | 8-K | 5.07 | 0001193125-22-176987 | 001-39269 | 221025881 | 34 | 154264 | 1 | 1 |
| 2022-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-038203 | 5587 | ||||||
| 2022-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-038201 | 5586 | ||||||
| 2022-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-038200 | 5556 | ||||||
| 2022-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-038199 | 5591 | ||||||
| 2022-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-22-038197 | 5587 | ||||||
| 2022-05-13 | 4 | FORM 4 SUBMISSION | 0001209191-22-028963 | 8979 | ||||||
| 2022-05-09 | 10-Q | 10-Q | 0000950170-22-008512 | 001-39269 | 22905352 | 34 | 8326251 | 1 | 1 | |
| 2022-05-09 | 8-K | 8-K | 2.02,9.01 | 0000950170-22-008492 | 001-39269 | 22905030 | 34 | 393263 | 1 | 1 |
| 2022-04-27 | EFFECT | xslEFFECTX01/primary_doc.xml | POS AM,0001193125-22-081609,2022-04-27 | 9999999995-22-001112 | 333-255833 | 22861930 | 33 | 1750 | ||
| 2022-04-27 | DEFA14A | DEFA14A | 0001193125-22-123601 | 001-39269 | 22859568 | 34 | 43232 | |||
| 2022-04-27 | DEF 14A | DEF 14A | 0001193125-22-123589 | 001-39269 | 22859515 | 34 | 387546 | |||
| 2022-03-31 | 4 | FORM 4 SUBMISSION | 0001209191-22-021875 | 5064 | ||||||
| 2022-03-25 | 4 | FORM 4 SUBMISSION | 0001209191-22-021153 | 8980 | ||||||
| 2022-03-22 | S-8 | S-8 | 0001193125-22-081616 | 333-263763 | 22759629 | 33 | 98724 | |||
| 2022-03-22 | POS AM | POS AM | 0001193125-22-081609 | 333-255833 | 22759585 | 33 | 543100 | |||
| 2022-03-21 | 8-K | 8-K | 7.01,9.01 | 0001193125-22-080683 | 001-39269 | 22756355 | 34 | 7780983 | 1 | 1 |
| 2022-03-21 | 10-K | 10-K | 0000950170-22-004239 | 001-39269 | 22756219 | 34 | 14147844 | 1 | 1 | |
| 2022-03-21 | 8-K | 8-K | 2.02,9.01 | 0001193125-22-080529 | 001-39269 | 22755794 | 34 | 237623 | 1 | 1 |
| 2022-03-21 | POSASR | POSASR | 0001193125-22-080510 | 333-255833 | 22755739 | 33 | 489316 | |||
| 2022-03-04 | 8-K | 8-K | 5.02,9.01 | 0001193125-22-066051 | 001-39269 | 22713976 | 34 | 431783 | 1 | 1 |
| 2022-02-14 | SC 13G/A | oricpharmaceuticals13ga.htm | 0000935836-22-000162 | 005-91490 | 22630106 | 34 | 47405 | |||
| 2022-02-11 | SC 13G/A | SC 13G/A | 0001193125-22-037274 | 005-91490 | 22622203 | 34 | 79075 | |||
| 2022-02-09 | SC 13G/A | filing.txt | 0000315066-22-001318 | 005-91490 | 22604789 | 34 | 8500 | |||
| 2022-02-03 | SC 13G/A | us68622p1093_020322.txt | 0000834237-22-006284 | 005-91490 | 22588994 | 34 | 13392 | |||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006339 | 7961 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006337 | 7960 | ||||||
| 2022-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-22-006336 | 7930 | ||||||
| 2022-02-02 | SC 13G | oricpharma13g_123121.htm | 0001040188-22-000052 | 005-91490 | 22583478 | 34 | 43847 | |||
| 2022-01-10 | 8-K | 8-K | 2.02,8.01,9.01 | 0001193125-22-005116 | 001-39269 | 22519776 | 34 | 180332 | 1 | 1 |
| 2021-11-16 | 4 | FORM 4 SUBMISSION | 0000899243-21-044836 | 27142 | ||||||
| 2021-11-10 | 4 | FORM 4 SUBMISSION | 0001209191-21-063926 | 5343 | ||||||
| 2021-11-10 | 3 | FORM 3 SUBMISSION | 0001209191-21-063925 | 5450 | ||||||
| 2021-11-10 | 8-K | 8-K | 5.02,9.01 | 0001193125-21-326034 | 001-39269 | 211396975 | 34 | 177861 | 1 | 1 |
| 2021-11-08 | 10-Q | 10-Q | 0000950170-21-003477 | 001-39269 | 211388296 | 34 | 7834440 | 1 | 1 | |
| 2021-11-08 | 8-K | 8-K | 2.02,9.01 | 0000950170-21-003470 | 001-39269 | 211388151 | 34 | 469044 | 1 | 1 |
| 2021-10-07 | 8-K | 8-K | 8.01,9.01 | 0001193125-21-294159 | 001-39269 | 211312454 | 34 | 196407 | 1 | 1 |
| 2021-09-16 | 4 | FORM 4 SUBMISSION | 0001209191-21-056461 | 8188 | ||||||
| 2021-09-16 | 4 | FORM 4 SUBMISSION | 0001209191-21-056460 | 7203 | ||||||
| 2021-09-14 | 4 | FORM 4 SUBMISSION | 0001209191-21-055871 | 8188 | ||||||
| 2021-09-14 | 4 | FORM 4 SUBMISSION | 0001209191-21-055866 | 7205 | ||||||
| 2021-09-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-055295 | 6031 | ||||||
| 2021-09-09 | 4 | FORM 4 SUBMISSION | 0001209191-21-055291 | 7202 | ||||||
| 2021-08-18 | 8-K | 8-K | 8.01 | 0001193125-21-249636 | 001-39269 | 211184951 | 34 | 147503 | 1 | 1 |
| 2021-08-16 | 4 | FORM 4 SUBMISSION | 0001209191-21-051657 | 5308 | ||||||
| 2021-08-16 | 3 | FORM 3 SUBMISSION | 0001209191-21-051654 | 5428 | ||||||
| 2021-08-16 | 8-K | 8-K | 1.01,5.02,9.01 | 0001193125-21-247855 | 001-39269 | 211179135 | 34 | 487361 | 1 | 1 |
| 2021-08-12 | SC 13D/A | AMENDMENT NO. 3 | 0000947871-21-000903 | 005-91490 | 211167806 | 34 | 115515 | |||
| 2021-08-10 | 10-Q | 10-Q | 0000950170-21-001185 | 001-39269 | 211160233 | 34 | 6433157 | 1 | 1 | |
| 2021-08-10 | 8-K | 8-K | 2.02,9.01 | 0000950170-21-001179 | 001-39269 | 211160094 | 34 | 426907 | 1 | 1 |
| 2021-07-12 | 8-K | 8-K | 8.01 | 0001193125-21-213171 | 001-39269 | 211086096 | 34 | 155499 | 1 | 1 |
| 2021-07-08 | 8-K | 8-K | 8.01,9.01 | 0001193125-21-210224 | 001-39269 | 211078899 | 34 | 174138 | 1 | 1 |
| 2021-06-21 | 8-K | 8-K | 5.07,8.01,9.01 | 0001193125-21-195039 | 001-39269 | 211030535 | 34 | 210699 | 1 | 1 |
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041747 | 7927 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041745 | 7978 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041743 | 7952 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041741 | 7940 | ||||||
| 2021-06-17 | 4 | FORM 4 SUBMISSION | 0001209191-21-041738 | 7969 | ||||||
| 2021-05-28 | 4 | FORM 4 SUBMISSION | 0001209191-21-036686 | 5200 | ||||||
| 2021-05-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-035525 | 9910 | ||||||
| 2021-05-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-035524 | 8717 | ||||||
| 2021-05-24 | 4 | FORM 4 SUBMISSION | 0001209191-21-035523 | 8764 | ||||||
| 2021-05-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-033817 | 13426 | ||||||
| 2021-05-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-033815 | 12228 | ||||||
| 2021-05-18 | 4 | FORM 4 SUBMISSION | 0001209191-21-033813 | 13812 | ||||||
| 2021-05-13 | 4 | FORM 4 SUBMISSION | 0001209191-21-032510 | 5594 | ||||||
| 2021-05-13 | 4 | FORM 4 SUBMISSION | 0001209191-21-032509 | 8716 | ||||||
| 2021-05-13 | 4 | FORM 4 SUBMISSION | 0001209191-21-032508 | 9198 | ||||||
| 2021-05-06 | 8-K | 8-K | 1.01,9.01 | 0001193125-21-153455 | 001-39269 | 21898899 | 34 | 251460 | ||
| 2021-05-06 | 424B5 | 424B5 | 0001193125-21-153432 | 333-255833 | 21898785 | 33 | 336496 | |||
| 2021-05-06 | S-3ASR | S-3ASR | 0001193125-21-153360 | 333-255833 | 21898412 | 33 | 596952 | |||
| 2021-05-06 | 10-Q | 10-Q | 0001564590-21-024997 | 001-39269 | 21898053 | 34 | 6069308 | 1 | 1 | |
| 2021-05-06 | 8-K | 8-K | 2.02,9.01 | 0001564590-21-024966 | 001-39269 | 21897831 | 34 | 199930 | ||
| 2021-04-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-029379 | 7319 | ||||||
| 2021-04-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-029378 | 6285 | ||||||
| 2021-04-30 | 4 | FORM 4 SUBMISSION | 0001209191-21-029375 | 7200 | ||||||
| 2021-04-26 | DEFA14A | DEFA14A | 0001193125-21-130240 | 001-39269 | 21851463 | 34 | 51055 | |||
| 2021-04-26 | DEF 14A | DEF 14A | 0001193125-21-130074 | 001-39269 | 21851427 | 34 | 390613 | |||
| 2021-04-05 | 4 | FORM 4 SUBMISSION | 0001209191-21-025495 | 4724 | ||||||
| 2021-04-05 | 4 | FORM 4 SUBMISSION | 0001209191-21-025493 | 5594 | ||||||
| 2021-04-05 | 4 | FORM 4 SUBMISSION | 0001209191-21-025492 | 5203 | ||||||
| 2021-03-31 | 4 | xslF345X03/ownership.xml | 0000947871-21-000400 | 8343 | ||||||
| 2021-03-31 | 4 | xslF345X03/ownership.xml | 0000947871-21-000399 | 10385 | ||||||
| 2021-03-26 | 4 | xslF345X03/ownership.xml | 0000947871-21-000396 | 12304 | ||||||
| 2021-03-26 | 4 | xslF345X03/ownership.xml | 0000947871-21-000395 | 10262 | ||||||
| 2021-03-23 | 4 | xslF345X03/ownership.xml | 0000947871-21-000361 | 10071 | ||||||
| 2021-03-23 | 4 | xslF345X03/ownership.xml | 0000947871-21-000360 | 12113 | ||||||
| 2021-03-23 | S-8 | S-8 | 0001193125-21-091284 | 333-254626 | 21765390 | 33 | 71434 | |||
| 2021-03-23 | 10-K | 10-K | 0001564590-21-014865 | 001-39269 | 21765027 | 34 | 11657066 | 1 | 1 | |
| 2021-03-23 | 8-K | ORIC_Q4 2020 EARNING RELEASE | 2.02,9.01 | 0001564590-21-014852 | 001-39269 | 21764906 | 34 | 295557 | ||
| 2021-03-22 | SC 13D/A | AMENDMENT NO. 2 | 0000947871-21-000353 | 005-91490 | 21759330 | 34 | 128481 | |||
| 2021-03-18 | 4 | xslF345X03/ownership.xml | 0000947871-21-000349 | 12298 | ||||||
| 2021-03-18 | 4 | xslF345X03/ownership.xml | 0000947871-21-000348 | 10256 | ||||||
| 2021-03-15 | 4 | xslF345X03/ownership.xml | 0000947871-21-000334 | 12485 | ||||||
| 2021-03-15 | 4 | xslF345X03/ownership.xml | 0000947871-21-000333 | 10257 | ||||||
| 2021-02-16 | SC 13G/A | oric13ga.htm | 0000935836-21-000155 | 005-91490 | 21634758 | 34 | 46920 | |||
| 2021-02-16 | SC 13G | SC 13G | 0001193125-21-042022 | 005-91490 | 21630688 | 34 | 93271 | |||
| 2021-02-08 | SC 13G/A | filing.txt | 0000315066-21-001170 | 005-91490 | 21599711 | 34 | 8462 | |||
| 2021-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-006964 | 5445 | ||||||
| 2021-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-006963 | 5464 | ||||||
| 2021-02-02 | 4 | FORM 4 SUBMISSION | 0001209191-21-006962 | 5436 | ||||||
| 2021-02-02 | SC 13G | us68622p1093_020221.txt | 0000834237-21-006936 | 005-91490 | 21580678 | 34 | 13296 | |||
| 2021-01-11 | 8-K | 8-K | 2.02,7.01,9.01 | 0001193125-21-005732 | 001-39269 | 21519046 | 34 | 21576516 | ||
| 2020-11-18 | SC 13D/A | AMENDMENT NO. 1 | 0000947871-20-000893 | 005-91490 | 201324430 | 34 | 115074 | |||
| 2020-11-13 | 424B4 | 424B4 | 0001193125-20-293217 | 333-250001 | 201312640 | 33 | 7660864 | |||
| 2020-11-12 | S-1MEF | S-1MEF | 0001193125-20-292166 | 333-250053 | 201309039 | 33 | 58776 | |||
| 2020-11-12 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-11-12 16:00:00 | 9999999995-20-003167 | 333-250001 | 201309004 | 33 | 1738 | ||
| 2020-11-10 | CORRESP | filename1.htm | 0001193125-20-290268 | 8901 | ||||||
| 2020-11-10 | CORRESP | filename1.htm | 0001193125-20-290260 | 7410 | ||||||
| 2020-11-10 | S-1 | S-1 | 0001193125-20-290157 | 333-250001 | 201301273 | 33 | 12763527 | 1 | ||
| 2020-11-05 | 10-Q | 10Q | 0001564590-20-051363 | 001-39269 | 201290901 | 34 | 7950644 | 1 | 1 | |
| 2020-11-05 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-051336 | 001-39269 | 201290722 | 34 | 297192 | ||
| 2020-11-05 | 4 | OWNERSHIP DOCUMENT | 0001104659-20-121613 | 11407 | ||||||
| 2020-11-05 | SC 13G/A | SC 13G/A | 0001104659-20-121611 | 005-91490 | 201288975 | 34 | 93484 | |||
| 2020-10-19 | 8-K | 8-K | 8.01,9.01 | 0001564590-20-046772 | 001-39269 | 201246289 | 34 | 81349 | ||
| 2020-08-05 | 10-Q | 10-Q | 0001564590-20-036836 | 001-39269 | 201077621 | 34 | 6688460 | 1 | 1 | |
| 2020-08-05 | 8-K | 8-K | 2.02,3.02,7.01,9.01 | 0001564590-20-036825 | 001-39269 | 201077489 | 34 | 307452 | ||
| 2020-07-28 | UPLOAD | filename1.pdf | 0000000000-20-006880 | 40483 | ||||||
| 2020-07-20 | DRS | filename1.htm | 0000950123-20-007048 | 377-03309 | 201036759 | 33 | 6855322 | |||
| 2020-06-10 | 4 | FORM 4 SUBMISSION | 0001209191-20-035596 | 5301 | ||||||
| 2020-06-10 | 3 | FORM 3 SUBMISSION | 0001209191-20-035595 | 6053 | ||||||
| 2020-06-10 | 8-K | 8-K | 5.02,9.01 | 0001564590-20-028816 | 001-39269 | 20953435 | 34 | 50333 | ||
| 2020-05-20 | 10-Q | 10-Q | 0001564590-20-026394 | 001-39269 | 20898516 | 34 | 4834418 | 1 | ||
| 2020-05-20 | 8-K | 8-K | 2.02,9.01 | 0001564590-20-026388 | 001-39269 | 20898437 | 34 | 239429 | ||
| 2020-05-11 | SC 13G | filing.txt | 0000315066-20-001492 | 005-91490 | 20862812 | 34 | 8441 | |||
| 2020-05-01 | SC 13G | oric13g2020.htm | 0000935836-20-000286 | 005-91490 | 20842003 | 34 | 47690 | |||
| 2020-05-01 | SC 13D | SCHEDULE 13D | 0000947871-20-000417 | 005-91490 | 20841042 | 34 | 119684 | |||
| 2020-04-29 | SC 13G | SCHEDULE 13G | 0001104659-20-052583 | 005-91490 | 20826878 | 34 | 108813 | |||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025998 | 22036 | ||||||
| 2020-04-28 | 8-K | 8-K | 5.03,7.01,9.01 | 0001564590-20-019302 | 001-39269 | 20826255 | 34 | 1185086 | ||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025990 | 20718 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025989 | 24694 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025987 | 19967 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025985 | 7048 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025984 | 8084 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025983 | 17888 | ||||||
| 2020-04-28 | 4 | FORM 4 SUBMISSION | 0001209191-20-025981 | 7093 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025810 | 5453 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025808 | 5443 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025807 | 5415 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025806 | 5354 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025805 | 5418 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025804 | 5377 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025803 | 5371 | ||||||
| 2020-04-27 | 4 | FORM 4 SUBMISSION | 0001209191-20-025801 | 5422 | ||||||
| 2020-04-24 | S-8 | S-8 | 0001193125-20-119249 | 333-237840 | 20815984 | 33 | 76223 | |||
| 2020-04-24 | 424B4 | 424B4 | 0001193125-20-119234 | 333-236792 | 20815928 | 33 | 5701007 | |||
| 2020-04-23 | EFFECT | xslEFFECTX01/primary_doc.xml | S-1,,2020-04-23 16:00:00 | 9999999995-20-000838 | 333-236792 | 20812380 | 33 | 1737 | ||
| 2020-04-23 | 3 | FORM 3 SUBMISSION | 0001209191-20-025500 | 11842 | ||||||
| 2020-04-23 | 3 | FORM 3 SUBMISSION | 0001209191-20-025498 | 10177 |
One latest value per concept from companyfacts (215 concepts). Full history stays in the JSON.
| Taxonomy | Tag | Label | Unit | Value | Start | End | FY | FP | Form | Filed | Accn |
|---|---|---|---|---|---|---|---|---|---|---|---|
| dei | EntityCommonStockSharesOutstanding | Entity Common Stock, Shares Outstanding | shares | 103.93M | 2026-11-09 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| dei | EntityPublicFloat | Entity Public Float | USD | 862.40M | 2025-06-30 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| ecd | NonPeoNeoAvgCompActuallyPaidAmt | NonPeoNeoAvgCompActuallyPaidAmt | USD | 2.30M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-28 | 0001193125-26-186911 | ||
| ecd | NonPeoNeoAvgTotalCompAmt | NonPeoNeoAvgTotalCompAmt | USD | 2.26M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-28 | 0001193125-26-186911 | ||
| ecd | PeoActuallyPaidCompAmt | PeoActuallyPaidCompAmt | USD | 5.69M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-28 | 0001193125-26-186911 | ||
| ecd | PeoTotalCompAmt | PeoTotalCompAmt | USD | 5.57M | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-28 | 0001193125-26-186911 | ||
| ecd | TotalShareholderRtnAmt | TotalShareholderRtnAmt | USD | 88.91 | 2025-01-01 | 2025-12-31 | DEF 14A | 2026-04-28 | 0001193125-26-186911 | ||
| ffd | NetFeeAmt | NetFeeAmt | USD | 1,667.98 | 2026-07-30 | S-8 | 2026-07-30 | 0001193125-26-326363 | |||
| ffd | TtlFeeAmt | TtlFeeAmt | USD | 1,667.98 | 2026-07-30 | S-8 | 2026-07-30 | 0001193125-26-326363 | |||
| ffd | TtlOfferingAmt | TtlOfferingAmt | USD | 12.08M | 2026-07-30 | S-8 | 2026-07-30 | 0001193125-26-326363 | |||
| ffd | TtlOffsetAmt | TtlOffsetAmt | USD | 0 | 2026-07-30 | S-8 | 2026-07-30 | 0001193125-26-326363 | |||
| us-gaap | AccountsPayableCurrent | Accounts Payable, Current | USD | 2.15M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AccretionAmortizationOfDiscountsAndPremiumsInvestments | Accretion (Amortization) of Discounts and Premiums, Investments | USD | -690,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | AccruedLiabilitiesCurrent | Accrued Liabilities, Current | USD | 22.63M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AccruedLiabilitiesCurrentAndNoncurrent | Accrued Liabilities | USD | 1.90M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | AccruedRentCurrent | Accrued Rent, Current | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | AccruedSalariesCurrent | Accrued Salaries, Current | USD | 7.33M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment | Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment | USD | 8.46M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AccumulatedOtherComprehensiveIncomeLossNetOfTax | Accumulated Other Comprehensive Income (Loss), Net of Tax | USD | -1.69M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AdditionalPaidInCapitalCommonStock | Additional Paid in Capital, Common Stock | USD | 1.16B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue | APIC, Share-based Payment Arrangement, Increase for Cost Recognition | USD | 6.19M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs | USD | 399,000 | 2022-01-01 | 2022-12-31 | 2023 | FY | 10-K | 2024-03-11 | 0000950170-24-029298 |
| us-gaap | AllocatedShareBasedCompensationExpense | Share-based Payment Arrangement, Expense | USD | 20.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | shares | 18.25M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | Assets | Assets | USD | 366.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AssetsCurrent | Assets, Current | USD | 274.75M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax | USD | 3,000 | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-10 | 0000950170-21-001185 | |
| us-gaap | AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax | Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax | USD | 31,000 | 2020-12-31 | 2021 | Q2 | 10-Q | 2021-08-10 | 0000950170-21-001185 | |
| us-gaap | AvailableForSaleDebtSecuritiesAmortizedCostBasis | Debt Securities, Available-for-sale, Amortized Cost | USD | 90.99M | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-10 | 0000950170-21-001185 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecurities | Debt Securities, Available-for-sale | USD | 90.99M | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-10 | 0000950170-21-001185 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesCurrent | Debt Securities, Available-for-sale, Current | USD | 227.53M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | AvailableForSaleSecuritiesDebtSecuritiesNoncurrent | Debt Securities, Available-for-sale, Noncurrent | USD | 83.99M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CashAndCashEquivalentsAtCarryingValue | Cash and Cash Equivalents, at Carrying Value | USD | 33.85M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | USD | 34.34M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect | USD | -11.82M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 | Class of Warrant or Right, Exercise Price of Warrants or Rights | USD/shares | 0 | 2025-05-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ClassOfWarrantOrRightOutstanding | Class of Warrant or Right, Outstanding | shares | 4.46M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CommonStockParOrStatedValuePerShare | Common Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CommonStockSharesAuthorized | Common Stock, Shares Authorized | shares | 1.00B | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CommonStockSharesIssued | Common Stock, Shares, Issued | shares | 103.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CommonStockSharesOutstanding | Common Stock, Shares, Outstanding | shares | 103.87M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | CommonStockValue | Common Stock, Value, Issued | USD | 11,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ComprehensiveIncomeNetOfTax | Comprehensive Income (Loss), Net of Tax, Attributable to Parent | USD | -127.81M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ConversionOfStockAmountConverted1 | Conversion of Stock, Amount Converted | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ConvertiblePreferredStockSharesIssuedUponConversion | Convertible Preferred Stock, Shares Issued upon Conversion | shares | 19.28M | 2020-04-30 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions | Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions | Security | 18 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | DeferredCosts | Deferred Costs, Noncurrent | USD | 1.34M | 2019-12-31 | 2020 | Q2 | 10-Q | 2020-08-05 | 0001564590-20-036836 | |
| us-gaap | DeferredOfferingCosts | Deferred Offering Costs | USD | 2.40M | 2020-03-31 | 2020 | Q1 | 10-Q | 2020-05-20 | 0001564590-20-026394 | |
| us-gaap | DeferredRentCreditNoncurrent | Deferred Rent Credit, Noncurrent | USD | 219,000 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | DeferredTaxAssetsGoodwillAndIntangibleAssets | Deferred Tax Assets, Goodwill and Intangible Assets | USD | 5.59M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsGross | Deferred Tax Assets, Gross | USD | 214.72M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsLiabilitiesNet | Deferred Tax Assets, Net | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsNet | Deferred Tax Assets, Net of Valuation Allowance | USD | 2.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsOperatingLossCarryforwards | Deferred Tax Assets, Operating Loss Carryforwards | USD | 129.33M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsTaxCreditCarryforwardsResearch | Deferred Tax Assets, Tax Credit Carryforwards, Research | USD | 24.63M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | USD | 18.52M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent | USD | 0 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsOther | Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Other | USD | 2.13M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxAssetsValuationAllowance | Deferred Tax Assets, Valuation Allowance | USD | 212.60M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxLiabilities | Deferred Tax Liabilities, Net | USD | 2.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs | USD | 32.43M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxLiabilitiesOther | Deferred Tax Liabilities, Other | USD | 220,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DeferredTaxLiabilitiesPropertyPlantAndEquipment | Deferred Tax Liabilities, Property, Plant and Equipment | USD | 29,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | DefinedContributionPlanCostRecognized | Defined Contribution Plan, Cost | USD | 900,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | DefinedContributionPlanEmployerDiscretionaryContributionAmount | Defined Contribution Plan, Employer Discretionary Contribution Amount | USD | 0 | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | Depreciation | Depreciation | USD | 813,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | EarningsPerShareBasic | Earnings Per Share, Basic | USD/shares | -1.17 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | EarningsPerShareBasicAndDiluted | Earnings Per Share, Basic and Diluted | USD/shares | -0.59 | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008512 |
| us-gaap | EarningsPerShareDiluted | Earnings Per Share, Diluted | USD/shares | -1.17 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | EffectiveIncomeTaxRateContinuingOperations | Effective Income Tax Rate Reconciliation, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | pure | 0.21 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent | pure | -0.235 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent | pure | -0.009 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Percent | pure | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent | pure | 0.001 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EffectiveIncomeTaxRateReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent | pure | 0.04 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized | Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount | USD | 36.40M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | ExchangeFees | Exchange Fees | USD | 0 | 2024-07-08 | 2024 | FY | 10-K | 2025-02-18 | 0000950170-25-022273 | |
| us-gaap | FairValueAssetsLevel1ToLevel2TransfersAmount | Fair Value, Assets, Level 1 to Level 2 Transfers, Amount | USD | 0 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008512 | |
| us-gaap | FairValueAssetsLevel2ToLevel1TransfersAmount | Fair Value, Assets, Level 2 to Level 1 Transfers, Amount | USD | 0 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008512 | |
| us-gaap | GainLossOnDispositionOfAssets1 | Gain (Loss) on Disposition of Assets | USD | 0 | 2024-01-01 | 2024-12-31 | 2024 | FY | 10-K | 2025-02-18 | 0000950170-25-022273 |
| us-gaap | GeneralAndAdministrativeExpense | General and Administrative Expense | USD | 25.38M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | IncomeTaxExaminationPenaltiesAndInterestAccrued | Income Tax Examination, Penalties and Interest Accrued | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | IncomeTaxExpenseBenefit | Income Tax Expense (Benefit) | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount | USD | 30.43M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount | USD | -27.19M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpense | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount | USD | 1.19M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount | USD | 766,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationOtherAdjustments | Effective Income Tax Rate Reconciliation, Other Adjustments, Amount | USD | -17,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationOtherReconcilingItems | Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount | USD | 132,000 | 2024-01-01 | 2024-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationStateAndLocalIncomeTaxes | Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount | USD | -186,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncomeTaxReconciliationTaxCreditsResearch | Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount | USD | 5.20M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | IncreaseDecreaseInAccountsPayableAndAccruedLiabilities | Increase (Decrease) in Accounts Payable and Accrued Liabilities | USD | 2.11M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets | Increase (Decrease) in Prepaid Expense and Other Assets | USD | 4.49M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | InterestIncomeExpenseNonoperatingNet | Interest Income (Expense), Nonoperating, Net | USD | 1.73M | 2023-01-01 | 2023-03-31 | 2023 | Q1 | 10-Q | 2023-05-08 | 0000950170-23-018839 |
| us-gaap | InterestIncomeOther | Interest Income, Other | USD | 0 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-07 | 0000950170-22-022631 |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDue | Lessee, Operating Lease, Liability, to be Paid | USD | 8.14M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive | Lessee, Operating Lease, Liability, to be Paid, after Year Five | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths | Lessee, Operating Lease, Liability, to be Paid, Year One | USD | 3.46M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFive | Lessee, Operating Lease, Liability, to be Paid, Year Five | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearFour | Lessee, Operating Lease, Liability, to be Paid, Year Four | USD | 0 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearThree | Lessee, Operating Lease, Liability, to be Paid, Year Three | USD | 1.18M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsDueYearTwo | Lessee, Operating Lease, Liability, to be Paid, Year Two | USD | 3.50M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear | Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year | USD | 492,000 | 2021-09-30 | 2021 | Q3 | 10-Q | 2021-11-08 | 0000950170-21-003477 | |
| us-gaap | LesseeOperatingLeaseLiabilityUndiscountedExcessAmount | Lessee, Operating Lease, Liability, Undiscounted Excess Amount | USD | 699,000 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | Liabilities | Liabilities | USD | 27.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | LiabilitiesAndStockholdersEquity | Liabilities and Equity | USD | 366.89M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | LiabilitiesCurrent | Liabilities, Current | USD | 24.78M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | LongTermDebt | Long-term Debt | USD | 10.50M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | MarketableSecurities | Marketable Securities | USD | 0 | 2019-12-31 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051363 | |
| us-gaap | MarketableSecuritiesCurrent | Marketable Securities, Current | USD | 90.99M | 2021-06-30 | 2021 | Q2 | 10-Q | 2021-08-10 | 0000950170-21-001185 | |
| us-gaap | NetCashProvidedByUsedInFinancingActivities | Net Cash Provided by (Used in) Financing Activities | USD | 62.77M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | NetCashProvidedByUsedInInvestingActivities | Net Cash Provided by (Used in) Investing Activities | USD | 31.43M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | NetCashProvidedByUsedInOperatingActivities | Net Cash Provided by (Used in) Operating Activities | USD | -106.03M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | NetIncomeLoss | Net Income (Loss) Attributable to Parent | USD | -125.33M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 | Noncash or Part Noncash Acquisition, Fixed Assets Acquired | USD | 436,000 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | NonoperatingIncomeExpense | Nonoperating Income (Expense) | USD | 11.13M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | NumberOfOperatingSegments | Number of Operating Segments | Segments | 1 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | OperatingExpenses | Operating Expenses | USD | 136.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | OperatingIncomeLoss | Operating Income (Loss) | USD | -136.47M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | OperatingLeaseCost | Operating Lease, Cost | USD | 3.11M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | OperatingLeaseExpense | Operating Lease, Expense | USD | 1.40M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | OperatingLeaseLiability | Operating Lease, Liability | USD | 7.44M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | OperatingLeaseLiabilityCurrent | Operating Lease, Liability, Current | USD | 3.35M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | OperatingLeaseLiabilityNoncurrent | Operating Lease, Liability, Noncurrent | USD | 4.11M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | OperatingLeasePayments | Operating Lease, Payments | USD | 3.31M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | OperatingLeaseRightOfUseAsset | Operating Lease, Right-of-Use Asset | USD | 6.66M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDue | Operating Leases, Future Minimum Payments Due | USD | 2.63M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueCurrent | Operating Leases, Future Minimum Payments Due, Next Twelve Months | USD | 1.94M | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInFourYears | Operating Leases, Future Minimum Payments, Due in Four Years | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInThreeYears | Operating Leases, Future Minimum Payments, Due in Three Years | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsDueInTwoYears | Operating Leases, Future Minimum Payments, Due in Two Years | USD | 686,000 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear | Operating Leases, Future Minimum Payments, Remainder of Fiscal Year | USD | 478,000 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051363 | |
| us-gaap | OperatingLeaseWeightedAverageDiscountRatePercent | Operating Lease, Weighted Average Discount Rate, Percent | pure | 0.084 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | OperatingLossCarryforwards | Operating Loss Carryforwards | USD | 424.30M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | OtherAccruedLiabilitiesCurrent | Other Accrued Liabilities, Current | USD | 1.76M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | OtherAssetsNoncurrent | Other Assets, Noncurrent | USD | 6.06M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | OtherComprehensiveIncomeLossNetOfTax | Other Comprehensive Income (Loss), Net of Tax | USD | -31,000 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 |
| us-gaap | OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax | OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax | USD | -2.48M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | OtherLiabilitiesNoncurrent | Other Liabilities, Noncurrent | USD | 2.61M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | OtherNonoperatingIncome | Other Nonoperating Income | USD | 0 | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008483 |
| us-gaap | PaymentsOfFinancingCosts | Payments of Financing Costs | USD | 1.64M | 2020-01-01 | 2020-03-31 | 2021 | Q1 | 10-Q | 2021-05-06 | 0001564590-21-024997 |
| us-gaap | PaymentsOfStockIssuanceCosts | Payments of Stock Issuance Costs | USD | 993,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | PaymentsToAcquireInvestments | Payments to Acquire Investments | USD | 143.10M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | PaymentsToAcquireMarketableSecurities | Payments to Acquire Marketable Securities | USD | 124.64M | 2020-01-01 | 2020-09-30 | 2020 | Q3 | 10-Q | 2020-11-05 | 0001564590-20-051363 |
| us-gaap | PaymentsToAcquirePropertyPlantAndEquipment | Payments to Acquire Property, Plant, and Equipment | USD | 465,000 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | PreferredStockParOrStatedValuePerShare | Preferred Stock, Par or Stated Value Per Share | USD/shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PreferredStockSharesAuthorized | Preferred Stock, Shares Authorized | shares | 200.00M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PreferredStockSharesIssued | Preferred Stock, Shares Issued | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PreferredStockSharesOutstanding | Preferred Stock, Shares Outstanding | shares | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PreferredStockValue | Preferred Stock, Value, Issued | USD | 0 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PrepaidExpenseAndOtherAssetsCurrent | Prepaid Expense and Other Assets, Current | USD | 13.38M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ProceedsFromIssuanceInitialPublicOffering | Proceeds from Issuance Initial Public Offering | USD | 138.00M | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 |
| us-gaap | ProceedsFromIssuanceOfCommonStock | Proceeds from Issuance of Common Stock | USD | 60.88M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ProceedsFromIssuanceOfPreferredStockAndPreferenceStock | Proceeds from Issuance of Preferred Stock and Preference Stock | USD | 354,000 | 2022-01-01 | 2022-09-30 | 2022 | Q3 | 10-Q | 2022-11-07 | 0000950170-22-022631 |
| us-gaap | ProceedsFromIssuanceOfPrivatePlacement | Proceeds from Issuance of Private Placement | USD | 125.00M | 2025-05-23 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ProceedsFromSaleAndMaturityOfMarketableSecurities | Proceeds from Sale and Maturity of Marketable Securities | USD | 175.00M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ProceedsFromSaleOfNotesReceivable | Proceeds from Sale of Notes Receivable | USD | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ProceedsFromStockOptionsExercised | Proceeds from Stock Options Exercised | USD | 2.21M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ProfitLoss | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | USD | -48.08M | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | PropertyPlantAndEquipmentGross | Property, Plant and Equipment, Gross | USD | 10.55M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | PropertyPlantAndEquipmentNet | Property, Plant and Equipment, Net | USD | 2.08M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ResearchAndDevelopmentExpense | Research and Development Expense | USD | 14.98M | 2020-01-01 | 2020-06-30 | 2020 | Q2 | 10-Q | 2020-08-05 | 0001564590-20-036836 |
| us-gaap | ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost | Research and Development Expense (Excluding Acquired in Process Cost) | USD | 111.09M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ResearchAndDevelopmentInProcess | Research and Development in Process | USD | 5.00M | 2022-01-01 | 2022-12-31 | 2022 | FY | 10-K | 2023-03-16 | 0000950170-23-008483 |
| us-gaap | RestrictedCashAndCashEquivalents | Restricted Cash and Cash Equivalents | USD | 491,000 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | RetainedEarningsAccumulatedDeficit | Retained Earnings (Accumulated Deficit) | USD | -817.58M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | SaleOfStockConsiderationReceivedOnTransaction | Sale of Stock, Consideration Received on Transaction | USD | 124.40M | 2025-05-23 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensation | Share-based Payment Arrangement, Noncash Expense | USD | 20.18M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | pure | 0 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | pure | 1.005 | 2019-01-01 | 2019-06-30 | 2020 | Q2 | 10-Q | 2020-08-05 | 0001564590-20-036836 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | pure | 0.884 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | pure | 0.823 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | pure | 0.026 | 2019-01-01 | 2019-06-30 | 2020 | Q2 | 10-Q | 2020-08-05 | 0001564590-20-036836 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum | pure | 0.013 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum | pure | 0.006 | 2021-01-01 | 2021-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value | USD | 80.48M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number | shares | 10.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price | USD/shares | 5.94 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value | USD | 2.30M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period | shares | 186,928 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price | USD/shares | 8.65 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares | 3.90M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | USD/shares | 6.22 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | USD | 112.49M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number | shares | 17.14M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | USD/shares | 6.99 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price | USD/shares | 4.67 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | USD/shares | 8.6 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | SharePrice | Share Price | USD/shares | 1.6 | 2018-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | SharesIssuedPricePerShare | Shares Issued, Price Per Share | USD/shares | 6.5 | 2025-05-23 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | StockholdersEquity | Stockholders' Equity Attributable to Parent | USD | 339.50M | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 | |
| us-gaap | StockholdersEquityNoteStockSplitConversionRatio1 | Stockholders' Equity Note, Stock Split, Conversion Ratio | pure | 0.25 | 2020-04-28 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | StockIssuedDuringPeriodSharesNewIssues | Stock Issued During Period, Shares, New Issues | shares | 14.13M | 2025-05-01 | 2025-05-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | StockIssuedDuringPeriodSharesStockOptionsExercised | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period | shares | 473,113 | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | StockIssuedDuringPeriodValueAcquisitions | Stock Issued During Period, Value, Acquisitions | USD | 19.84M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | StockIssuedDuringPeriodValueConversionOfConvertibleSecurities | Stock Issued During Period, Value, Conversion of Convertible Securities | USD | 178.06M | 2020-01-01 | 2020-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 |
| us-gaap | StockIssuedDuringPeriodValueEmployeeStockPurchasePlan | Stock Issued During Period, Value, Employee Stock Purchase Plan | USD | 679,000 | 2026-04-01 | 2026-06-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | StockIssuedDuringPeriodValueNewIssues | Stock Issued During Period, Value, New Issues | USD | 59.89M | 2026-01-01 | 2026-03-31 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | StockIssuedDuringPeriodValueStockOptionsExercised | Stock Issued During Period, Value, Stock Options Exercised | USD | 806,000 | 2026-07-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit | Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit) | USD | 0 | 2020-01-01 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 |
| us-gaap | TemporaryEquityCarryingAmountAttributableToParent | Temporary Equity, Carrying Amount, Attributable to Parent | USD | 178.06M | 2019-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | TemporaryEquityLiquidationPreference | Temporary Equity, Liquidation Preference | USD | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | TemporaryEquityParOrStatedValuePerShare | Temporary Equity, Par or Stated Value Per Share | USD/shares | 0 | 2020-12-31 | 2020 | FY | 10-K | 2021-03-23 | 0001564590-21-014865 | |
| us-gaap | TemporaryEquitySharesAuthorized | Temporary Equity, Shares Authorized | shares | 20.35M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | TemporaryEquitySharesIssued | Temporary Equity, Shares Issued | shares | 19.28M | 2019-12-31 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | TemporaryEquitySharesOutstanding | Temporary Equity, Shares Outstanding | shares | 0 | 2020-04-30 | 2021 | FY | 10-K | 2022-03-21 | 0000950170-22-004239 | |
| us-gaap | UnrecognizedTaxBenefits | Unrecognized Tax Benefits | USD | 4.77M | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 | |
| us-gaap | UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense | USD | 0 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions | Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions | USD | 1.04M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | UnrecognizedTaxBenefitsPeriodIncreaseDecrease | Unrecognized Tax Benefits, Period Increase (Decrease) | USD | 965,000 | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | ValuationAllowanceDeferredTaxAssetChangeInAmount | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount | USD | 40.00M | 2025-01-01 | 2025-12-31 | 2025 | FY | 10-K | 2026-02-23 | 0001193125-26-064005 |
| us-gaap | WeightedAverageNumberOfDilutedSharesOutstanding | Weighted Average Number of Shares Outstanding, Diluted | shares | 107.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |
| us-gaap | WeightedAverageNumberOfShareOutstandingBasicAndDiluted | Weighted Average Number of Shares Outstanding, Basic and Diluted | shares | 39.43M | 2022-01-01 | 2022-03-31 | 2022 | Q1 | 10-Q | 2022-05-09 | 0000950170-22-008512 |
| us-gaap | WeightedAverageNumberOfSharesOutstandingBasic | Weighted Average Number of Shares Outstanding, Basic | shares | 107.23M | 2026-01-01 | 2026-09-30 | 2026 | Q3 | 10-Q | 2026-11-16 | 0001193125-26-463577 |